Last reviewed · How we verify
Drospirenone and Ethinyl Estradiol tablets
Drospirenone and ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity.
Drospirenone and ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity. Used for Oral contraception for prevention of pregnancy, Treatment of acne vulgaris (in some formulations), Treatment of premenstrual dysphoric disorder (PMDD).
At a glance
| Generic name | Drospirenone and Ethinyl Estradiol tablets |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Drug class | Combined oral contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Drospirenone is a fourth-generation progestin with antimineralocorticoid and antiandrogenic properties, while ethinyl estradiol is a synthetic estrogen. Together, they inhibit the luteinizing hormone (LH) surge and follicle-stimulating hormone (FSH) secretion, preventing ovulation. The combination also thickens cervical mucus and alters the endometrium to reduce sperm penetration and implantation.
Approved indications
- Oral contraception for prevention of pregnancy
- Treatment of acne vulgaris (in some formulations)
- Treatment of premenstrual dysphoric disorder (PMDD)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
- Hypertension
Key clinical trials
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
- Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS (NA)
- Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS (NA)
- A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) (PHASE1)
- Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants (PHASE1)
- A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood (PHASE1)
- Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?! (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: